GW Pharmaceuticals’ Epidiolex (cannabidiol) Receives FDA Approval for Epilepsy for 2yrs. or older

 GW Pharmaceuticals’ Epidiolex (cannabidiol) Receives FDA Approval for Epilepsy for 2yrs. or older

GW Pharmaceuticals’ Epidiolex (cannabidiol) Receives FDA Approval for Epilepsy for 2yrs. or older

Shots:

  • The approval is based on three P-III studies results assessing Epidiolex (cannabidiol, PO) vs PBO in 516 patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome aged ≥ 2yrs.
  • The study demonstrated in reduction in frequency of seizures
  • Epidiolex (cannabidiol, PO) is an oral anti-epileptic drug and has received FDA’s PR, FT, & OD designation on 27 Jun, 2018, Jun, 2014, & 28 Feb, 2014 respectively and has also received EMA’s ODD for treating west syndrome & TSC

Click here to read full press release/ article | Ref: GW Pharmaceuticals | Image: Hempbizjournal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post